<DOC>
	<DOCNO>NCT00000560</DOCNO>
	<brief_summary>To determine addition beta-blocker standard therapy Class III Class IV heart failure patient reduce total mortality .</brief_summary>
	<brief_title>Beta-Blocker Evaluation Survival Trial ( BEST )</brief_title>
	<detailed_description>BACKGROUND : Controlled uncontrolled study suggest beta-blockade improves ventricular function congestive heart failure . Several trial suggest beta-blockers may also reduce mortality . In Beta-Blocker Heart Attack Trial , patient history heart failure less cardiac sudden-death mortality . Patients low ejection fraction Cardiac Arrhythmia Suppression Trial treat beta-blockade also reduction mortality . The Metoprolol Dilated Cardiomyopathy trial randomize patient dilated cardiomyopathy treatment metoprolol placebo . There trend toward reduction morbidity mortality endpoint patient treat metoprolol , due entirely reduction need cardiac transplantation . Thus , despite reasonable theoretical basis suggestive clinical study , concept beta-blockers reduce mortality congestive heart failure patient unproved . DESIGN NARRATIVE : Randomized , double-blind , multicenter . Patients assigned standard therapy plus addition beta-blocker ( bucindolol ) versus placebo . The primary endpoint total mortality . A radionuclide ventriculogram perform within 60 day randomization . History , physical examination , clinical laboratory study , chest x-ray , electrocardiogram , plasma norepinephrine level obtain within 14 day randomization . Patients stratify hospital , congestive heart failure etiology , ejection fraction , gender , assign treatment group adaptive balancing scheme ( `` bias coin '' randomization ) . Patients randomize either placebo plus standard congestive heart failure treatment beta-blocker plus standard congestive heart failure treatment follow minimum 18 month . The three year recruitment period begin May 1995 first 35 site . An additional 55 site begin recruitment August 14 , 1995 . Recruitment end December , 1998 enrollment 2,708 patient .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Adrenergic Agents</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<criteria>Men woman , age 18 . Patients compensate congestive heart failure due idiopathic dilate cardiomyopathy coronary disease ejection fraction less equal 0.35 , New York Heart Association functional class III IV , take angiotensinconverting enzyme inhibitor , digitalis , need , diuretic . Patients specific indication , contraindication , betablockade exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2005</verification_date>
</DOC>